PRESENTATION TITLE

A medical oncology conservative's viewpoint of the near-future state of germ cell tumor management:  Right Patient, Right Time, Right Intervention, and a bit more

PRESENTER(S)
Craig R. Nichols, M.D., FACP
Founder and Director, Testicular Cancer Commons, Beaverton, Oregon

PRESENTER BIO

Dr. Craig Nichols is originally from Oregon. After training in Medicine (Louisiana) and Hematology (Miami), he completed his specialty training at Indiana University (IU) where he focused on clinical trials in germ cell tumors and lymphoma, his clinical areas of expertise. He subsequently returned to Oregon where he joined the Oregon Health & Science University Cancer Institute and served as the division chief for hematology/oncology and vice chair for cancer clinical research.

Over the last decade, Dr. Nichols has served on the board of LIVESTRONG and the Oregon chapter of the Leukemia/Lymphoma Society. He also runs a nonprofit dedicated to information and knowledge exchange in testicular cancer. 

Dr. Nichols continues to serve as the executive officer for one of the nation’s largest cancer research groups — SWOG — for community-based cancer research, adolescent and young adult oncology, survivorship, patient advocacy and digital engagement. He was recently elected to the board of the American Society of Clinical Oncology and serves on its executive committee.

Dr. Nichols has had a career-long passion for cancer clinical research and more recently cancer care delivery, big data and comparative effectiveness research. He hopes to be broadly active in cancer clinical research at Intermountain through the Precision Medicine clinic with a focus on early phase molecular agents. He will continue his leadership in national research organizations as well as bringing cancer care delivery research to Intermountain through the NW NCORP partnership. He will remain clinically active, especially around providing cutting edge therapeutics to patients as well as focusing on adolescent and young adult oncology, lymphoma, and testicular cancer.

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Review the investigative timeline in germ cell tumors over the first 50 years.
• Identify the areas of uncertainty in the current standard management framework that lead to sub-optimal decision making, over- and under- treatment and unnecessary patient burden.
• Review operating characteristics of plasma expression of miR371
• Project the implications of integration of a high positive and negative predictive value liquid biomarker on the current germ cell tumor management framework.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.